This podcast touches on the lack of innovation in pharma and criticism about outsourcing innovation. Do these criticisms ignore recent technological advances in biotech (and the convergence of AI and genomics) that have reduced the minimum efficient scale in drug discovery creating new opportunities for startups, small firms, and scientist entrepreneurs? When we think of therapeutics as dispensing knowledge packed into a capsule or syringe, knowledge that has properties of both a private and public good (i.e. non-rival and partially excludable) scientist entrepreneurs are better incentivized and able to capture greater value from their discoveries in a venture capital funded startup environment than a larger institution like pharmaceutical companies or universities (even with Bayh-Dole Act). Drug discovery is risky, but by combining option value and discovery of new information with staged investment VC firms can discover positive NPV projects that would otherwise be rejected under conventional financing models. The combination of technological change, the economics of knowledge, and venture capital seems to reduce the comparative advantage of innovating 'in-house.' Maybe it is the case that large pharmaceutical firms have more of a comparative advantage navigating the valley of death that lies between a discovery and a cure by focusing on the regulatory approvals and marketing efforts necessary to deliver those products than they have in drug discovery?
No comments:
Post a Comment